新華社(she)(she)北京3月20日(ri)電 國務院辦(ban)公廳日(ri)前印發《》（以下簡稱《意見(jian)》）。《意見(jian)》堅持以習近平(ping)新時代(dai)中(zhong)國特色社(she)(she)會主義思想為(wei)(wei)指導，全面(mian)貫(guan)徹黨的(de)二(er)十大和二(er)十屆二(er)中(zhong)、三中(zhong)全會精神，以提升中(zhong)藥(yao)質(zhi)量(liang)為(wei)(wei)基(ji)礎，以科技創新為(wei)(wei)支撐，以體制機制改革(ge)為(wei)(wei)保(bao)障，形成傳承創新并重、布(bu)局(ju)結構合(he)理、裝備(bei)制造先進(jin)、質(zhi)量(liang)安全可(ke)靠、競爭(zheng)能力強的(de)中(zhong)醫(yi)藥(yao)產業高(gao)質(zhi)量(liang)發展格局(ju)，更好(hao)增進(jin)人民(min)健康福祉和服(fu)務中(zhong)國式現代(dai)化，從8個方面(mian)提出21項重點內容。

  一(yi)要加(jia)強中(zhong)(zhong)藥(yao)(yao)資(zi)源(yuan)(yuan)(yuan)保(bao)護利(li)用(yong)。加(jia)大中(zhong)(zhong)藥(yao)(yao)資(zi)源(yuan)(yuan)(yuan)保(bao)護力度，研究(jiu)修訂《野生藥(yao)(yao)材資(zi)源(yuan)(yuan)(yuan)保(bao)護管(guan)理條例》。規范(fan)珍稀中(zhong)(zhong)藥(yao)(yao)資(zi)源(yuan)(yuan)(yuan)開發利(li)用(yong)，突破一(yi)批珍稀中(zhong)(zhong)藥(yao)(yao)資(zi)源(yuan)(yuan)(yuan)的繁育、仿生、替代(dai)技術。推(tui)進中(zhong)(zhong)藥(yao)(yao)資(zi)源(yuan)(yuan)(yuan)統計監測。

  二(er)要提升中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)產業發展(zhan)水(shui)平。發展(zhan)中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)現代種業，加強(qiang)中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)種質資源(yuan)保護和利用。推進中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)生(sheng)態種植(zhi)養殖，因地制宜發展(zhan)林(lin)草中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)。加強(qiang)中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)流通和儲備(bei)體系建設，加強(qiang)中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)市場管理，完善中(zhong)(zhong)(zhong)藥(yao)材(cai)(cai)價格監管機制。

  三要加快推(tui)進中(zhong)藥(yao)(yao)產業(ye)(ye)轉型升(sheng)級。優(you)化(hua)產業(ye)(ye)結構布局，發展(zhan)優(you)勢(shi)產業(ye)(ye)集群(qun)。提升(sheng)中(zhong)藥(yao)(yao)制造(zao)品(pin)質(zhi)，推(tui)進中(zhong)藥(yao)(yao)工業(ye)(ye)數字(zi)化(hua)智能(neng)化(hua)發展(zhan)。培育(yu)名優(you)中(zhong)藥(yao)(yao)品(pin)種，加強中(zhong)藥(yao)(yao)炮制技(ji)術傳(chuan)承創(chuang)新(xin)，支持中(zhong)藥(yao)(yao)大品(pin)種創(chuang)新(xin)改(gai)良。打造(zao)知(zhi)名中(zhong)藥(yao)(yao)品(pin)牌。

  四要推進(jin)中(zhong)藥藥品價值評(ping)估和配備(bei)使(shi)用(yong)(yong)。開發中(zhong)醫藥臨(lin)床療效評(ping)價大模型，促進(jin)人用(yong)(yong)經驗(yan)向臨(lin)床證據轉(zhuan)化。加強中(zhong)藥配備(bei)使(shi)用(yong)(yong)，優化中(zhong)藥集中(zhong)采購、招(zhao)標采購政策，實現(xian)優質優價。

  五要(yao)推進中(zhong)藥(yao)(yao)科(ke)技(ji)創(chuang)新。加強中(zhong)醫(yi)(yi)類國(guo)家(jia)(jia)醫(yi)(yi)學中(zhong)心(xin)和中(zhong)藥(yao)(yao)領域全國(guo)重點(dian)實驗(yan)室(shi)、國(guo)家(jia)(jia)技(ji)術創(chuang)新中(zhong)心(xin)、國(guo)家(jia)(jia)制造業創(chuang)新中(zhong)心(xin)建設。加大國(guo)家(jia)(jia)科(ke)技(ji)計劃對(dui)中(zhong)藥(yao)(yao)的支持(chi)力度，加強對(dui)醫(yi)(yi)療機構中(zhong)藥(yao)(yao)制劑、名醫(yi)(yi)驗(yan)方等的挖掘(jue)和轉(zhuan)化。

  六要強化(hua)中(zhong)(zhong)(zhong)藥質(zhi)量監管。完(wan)善中(zhong)(zhong)(zhong)藥標(biao)準(zhun)體(ti)系(xi)，加(jia)快中(zhong)(zhong)(zhong)藥數字化(hua)標(biao)準(zhun)推廣。健全中(zhong)(zhong)(zhong)藥監管體(ti)系(xi)，理順中(zhong)(zhong)(zhong)藥品種保(bao)護審評管理體(ti)制，逐步完(wan)善中(zhong)(zhong)(zhong)成藥批準(zhun)文(wen)號退出機(ji)制。

  七要推(tui)(tui)動(dong)中(zhong)藥(yao)開放發(fa)展。促(cu)進更高水平開放，推(tui)(tui)動(dong)中(zhong)藥(yao)產品國際注冊和市場開拓。維護產業發(fa)展安全(quan)。

  八要提高綜(zong)合治(zhi)理能力和保障水平。加(jia)(jia)強(qiang)統籌領導，推進人(ren)才隊伍建設，加(jia)(jia)強(qiang)資金支持。